Sort by
Refine Your Search
-
Category
-
Country
-
Program
-
Field
-
co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and
-
at the School of Engineering & Materials Science, Queen Mary University of London, working closely with researchers at the Digital Environment Research Institute & Barts Heart Centre. Barts Heart Centre provides
-
enquiries should be addressed to e.gillay@qmul.ac.uk About Queen Mary At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable. Throughout our
-
the ability to inspire and mentor a team effectively and work well effectively with business stakeholders. About the Department At Queen Mary University of London, our aim is to become the most inclusive
-
University, Queen Mary University of London, and the University of Sheffield. This role offers extensive opportunities for professional development and experience across multiple research projects—ideal
-
embryos This Human Frontier Science Program (HFSP) (link is external) funded project is in collaboration with the labs of Hervé Turlier (CIRB-CNRS) and Chema Martin (Queen Mary University of London). We
-
University, Queen Mary University of London, and the University of Sheffield. This role offers extensive opportunities for professional development and experience across multiple research projects—ideal
-
. About Queen Mary At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable. Throughout our history, we’ve fostered social justice and improved
-
-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and improving
-
co-led by Queen Mary University of London. PharosAI is set to revolutionise AI-powered cancer care, accelerating the development of breakthrough therapies, advancing clinical applications, and